其它产品项目整合

项目整合的本质是一项集合成方法学、反应工程学与过程分析技术于一体的系统工程。其核心逻辑可以概括为以下几点：源头优选：利用如N-硝胺化学等底层方法学突破，从分子层面颠覆传统高成本、高污染路线。过程强化：依托连续流技术，攻克有机金属试剂应用、光化学反应放大等“不可能”任务，实现高危工艺的本质安全。系统集成：整合“反应-淬灭-分离”全流程，利用微流控与在线分析技术，消除批次间的差异，实现药品制造的连续化与智能化。当前，中间体工艺研发正在经历从“经验驱动”向“数据驱动”的转变。AI辅助路线设计、自动化高通量筛选与连续制造平台的结合，将使得“分子结构与最优工艺路径”之间的映射关系逐渐清晰。未来的竞争优势，将属于那些能够将底层化学创新与先进工程技术进行无缝整合的研发体系。
备注: 根据相关法律法规, 本站点不显示有法律约束管制的产品, 如有遗漏, 请自行鉴别,或提交我们及时更新撤除.
如有产品相关项目调研推广服务, 请致函联系我们

客户展示

其它产品项目整合

Bortezomib CAS Registry Number: 179324-69-7 硼替佐米

CAS Name: [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid
Additional Names: N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boronic acidTrade...
Literature References: Dipeptide boronic acid proteasome inhibitor. Prepn: J. Adams et al., WO 9613266; eidem, US 5780454 (1996, 1998 both to ProScript); idem et al., Bioorg. Med. Chem. Lett. 8, 333 (1998). Pharmacology and cytotoxic activity: idem et al., Cancer Res. 59, 2615 (1999). Crystal structure in complex with the yeast 20S proteasome: M. Groll et al., Structure 14, 451 (2006). Mechanism of action study: J. Codony-Servat et al., Mol. Cancer Ther. 5, 665 (2006). Clinical trial in refractory myeloma: P. G. Richardson et al., N. Engl. J. Med. 348, 2609 (2003). Review of clinical development: idem et al., Annu. Rev. Med. 57, 33-47 (2006).

Aspartame CAS Registry Number: 22839-47-0 阿斯巴甜

CAS Name: N-L-a-Aspartyl-L-phenylalanine 1-methyl ester
Additional Names: 3-amino-N-(a-carboxyphenethyl)succinamic acid N-methyl ester; APMTrademarks: Equal (NutraSweet Co.); NutraSweet (NutraS...
Literature References: Dipeptide ester about 160 times sweeter than sucrose in aqueous solution. Prepn: Davey et al., J. Chem. Soc. C 1966, 555; J. M. Schlatter, ZA 6702190; idem, US 3492131 (1968, 1970 both to Searle); H. Pietsch, Tetrahedron Lett. 1976, 4053; K. J. Vinick, S. Jung, ibid. 23, 1315 (1982); utilizing immobilized enzyme technology: C. Fuganti, P. Grasselli, ibid. 27, 3191 (1986). Structure-taste relationship: Mazur et al., J. Am. Chem. Soc. 91, 2684 (1969). Potential as a low-calorie sweetener: Cloninger, Baldwin, Science 170, 81 (1970). Metabolism: Oppermann et al., J. Nutr. 103, 1454, 1460 (1973).

Vildagliptin CAS Registry Number: 274901-16-5 维达列汀

CAS Name: (2S)-1-[[(3-Hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]acetyl]-2-pyrrolidinecarbonitrile
Additional Names: 1-[[(3-hydroxy-1-adamantyl) amino]acetyl]-2-cyano-(S)-pyrrolidineTrademarks: ...
Literature References: Dipeptidyl peptidase-IV (DPP-IV) inhibitor. Prepn: E. Villhauer, WO 0034241; idem, US 6166063 (both 2000 to Novartis); and pharmacology: idem et al., J. Med. Chem. 46, 2774 (2003). Clinical evaluation in type 2 diabetes: B. Ahrén et al., J. Clin. Endocrinol. Metab. 89, 2078 (2004); in combination with metformin: idem et al., Diabetes Care 27, 2874 (2004). Review of development and therapeutic potential: D. Barlocco, Curr. Opin. Invest. Drugs 5, 1094-1100 (2004).

Beclobrate CAS Registry Number: 55937-99-0 苄氯贝特

CAS Name: 2-[4-[(4-Chlorophenyl)methyl]phenoxy]-2-methylbutanoic acid ethyl ester
Additional Names: (±)-2-methyl-2-[p-(p'-chlorobenzyl)phenoxy]butyric acid ethyl ester; ethyl (±)-2-[[...
Literature References: Diphenylmethane derivative. Prepn: K. Thiele et al., DE 2461069; eidem, US 4483999 (1975, 1984 both to Siegfried); eidem, Arzneim.-Forsch. 29, 711 (1979). Preliminary clinical trial in hyperlipidemia: C. Najemnik et al., ibid. 31, 2168 (1981). Series of articles on pharmacology: ibid. 33, 1464-1472 (1983). Metabolism: W. Roth et al., ibid. 35, 244 (1985). Pharmacokinetics: I. Gikalov, U. Ifflaender, ibid. 37, 1065 (1987).

Lomerizine CAS Registry Number: 101477-55-8 洛美利嗪

CAS Name: 1-[Bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine
Additional Names: 1-[bis(p-fluorophenyl)methyl]-4-(2,3,4-trimethoxybenzyl)piperazine; 1-(2,3,4-trimethoxyben...
Literature References: Diphenylpiperazine calcium channel blocker; selective cerebral vasodilator. Prepn: H. Ohtaka et al., EP 159566; eidem, US 4663325 (1985, 1987 both to Kanebo); eidem et al., Chem. Pharm. Bull. 35, 3270 (1987). Structure-activity study: H. Ohtaka, G. Tsukamoto, ibid. 4117. HPLC determn in plasma and brain tissue: H. Waki, S. Ando, J. Chromatogr. 494, 408 (1989). Pharmacology: T. Kanazawa et al., J. Cardiovasc. Pharmacol. 16, 430 (1990). Protective effect in cerebral ischemia: H. Hara et al., Arch. Int. Pharmacodyn. 304, 206 (1990); V. Danielisova, M. Chavko, Neurochem. Res. 19, 1503 (1994).

Dipivefrin CAS Registry Number: 52365-63-6 地匹福林

CAS Name: 2,2-Dimethylpropanoic acid 4-[1-hydroxy-2-(methylamino)ethyl]-1,2-phenylene ester
Additional Names: (±)-3,4-dihydroxy-a-[(methylamino)methyl]benzyl alcohol 3,4-dipivalate; 1-(3',...
Literature References: Dipivalyl ester of epinephrine, q.v. Prepn: D. Henschler et al., DE 2152058; eidem, US 4085270 (1973, 1978 both to Klinge); A. Hussain, J. E. Truelove, DE 2343657; eidem, US 3809714 and US 3839584 (all 1974 to Interx). In vitro study: A. H. Neufeld, E. D. Page, Invest. Ophthalmol. Visual Sci. 16, 1118 (1977). Pharmacology: B. C. Wang et al., J. Pharmacol. Exp. Ther. 203, 442 (1977). Effects on intraocular pressure in dogs: R. M. Gwin et al., Am. J. Vet. Res. 39, 83 (1978). Metabolism: I. Abramovsky, J. S. Mindel, Arch. Ophthalmol. 97, 1937 (1979). Clinical study: M. A. Kass et al., ibid. 1865. General pharmacology, toxicology and clinical experience in glaucoma: D. A. McClure, ACS Symp. Ser. 14, 224-235 (1975). Comprehensive description: G. M. Wall, T. Y. Fan, Anal. Profiles Drug Subs. Excip. 22, 229-262 (1993).

Dimethyl Sulfoxide CAS Registry Number: 67-68-5 二甲基亚砜

CAS Name: Sulfinylbismethane
Additional Names: methyl sulfoxide; DMSOTrademarks: Deltan (Berna); Dolicur (Schering AG); Domoso (Syntex); Kemsol (Carter Horner); Rheumabene (Merckle); Rimso-50 (...
Literature References: Dipolar, aprotic solvent. Attributed with a wide range of bioactivities including analgesic, anti-inflammatory and cryoprotective properties. Prepn: A. Saytzeff, Ann. 144, 148 (1867). Usually obtained as a by-product of paper manufacture: M. D. Robbins, Chem. Eng. 68, 100 (June 26, 1961). Toxicity data: W. Bartsch et al., Arzneim.-Forsch. 26, 1581 (1976). Review of properties and use in organic chemistry: D. Martin et al., Angew. Chem. Int. Ed. 6, 318-334 (1967). Reviews of pharmacology and toxicology: S. W. Jacob, D. C. Wood, Arzneim.-Forsch. 17, 1553-1560 (1967); N. A. David, Annu. Rev. Pharmacol. 12, 353-374 (1972); of clinical experience: Ann. N.Y. Acad. Sci. 411, entitled "Biological Actions and Medical Applications of Dimethyl Sulfoxide", J. C. de la Torre, Ed. (1983) 402 pp; B. N. Swanson, Rev. Clin. Basic Pharmacol. 5, 1-33 (1985); of use in rheumatic disorders: J. M. Trice, R. S. Pinals, Semin. Arthritis Rheum. 15, 45-60 (1985). Review of veterinary uses: C. F. Brayton, Cornell Vet. 76, 61-90 (1986).

Dantrolene CAS Registry Number: 7261-97-4 1-(((5-(4-硝基苯基)呋喃-2-基)亚甲基)氨基)咪唑烷-2,4-二酮

CAS Name: 1-[[[5-(4-Nitrophenyl)-2-furanyl]methylene]amino]-2,4-imidazolidinedione
Additional Names: 1-[[5-(p-nitrophenyl)furfurylidene]amino]hydantoin
Percent Composition: C 53.51%, H 3.21%...
Literature References: Direct acting skeletal muscle relaxant; probably inhibits the release of calcium from the sarcoplasmic reticulum of skeletal muscle. Prepn: NL 6612588; Davis, Snyder, US 3415821 (1967, 1968 both to Norwich Pharmacal); Snyder et al., J. Med. Chem. 10, 807 (1967); Frimm et al., Chem. Zvesti 23, 916 (1969). HPLC determn in plasma: M. Lalande et al., J. Chromatogr. 430, 187 (1988). Toxicity data: K. O. Ellis et al., J. Pharm. Sci. 69, 327 (1980). Review of pharmacology: G. G. Harrison, Br. J. Anaesth. 60, 279 (1988); and therapeutic use: A. Ward et al., Drugs 32, 130-168 (1986). Review of efficacy in malignant hyperthermia: R. Ben Abraham et al., Q. J. Med. 90, 13-18 (1997).

Shvo Catalyst CAS Registry Number: 104439-77-2

CAS Name: Tetracarbonyl-m-hydro[(1,2,3,4,5-h)-1-hydroxylato-2,3,4,5-tetraphenyl-2,4-cyclopentadien-1-yl][(1,2,3,4,5-h)-1-hydroxy-2,3,4,5-tetraphenyl-2,4-cyclopentadien-1-yl]diruthenium
Addition...
Literature References: Diruthenium catalyst especially for hydrogen-transfer reactions. Prepn: Y. Blum, Y. Shvo, J. Organomet. Chem. 282, C7 (1985); Y. Shvo et al., J. Am. Chem. Soc. 108, 7400 (1986). X-ray structure study: M. J. Mays et al., Organometallics 8, 1162 (1989). Mechanism of hydrogen transfer: J. B. Johnson, J.-E. Bäckvall, J. Org. Chem. 68, 7681 (2003). Catalytic disproportionation of aldehydes: N. Menashe, Y. Shvo, Organometallics 10, 3885 (1991). Resolution of alcohols: B. A. Persson et al., J. Am. Chem. Soc. 121, 1645 (1999); oxidation of alcohols: J. H. Choi et al., Tetrahedron Lett. 45, 4607 (2004). Brief review: R. Prabhakaran, Synlett 2004, 2048-2049.

Chondrosine CAS Registry Number: 499-14-9 2-氨基-2-脱氧-3-O-(Β-D-吡喃葡糖醛酸)-Β-D-吡喃半乳糖

CAS Name: 2-Amino-2-deoxy-3-O-b-D-glucopyranurosyl-D-galactose
Additional Names: b-D-glucopyranosyluronic acid 2-deoxy-2-amino-D-galactose
Percent Composition: C 40.57%, H 5.96%, N 3.94%, O ...
Literature References: Disaccharide unit of chondroitins 4-sulfate and 6-sulfate. Isoln: Hebting, Biochem. Z. 63, 353 (1914); Levene, J. Biol. Chem. 140, 267 (1941); Wolfrom et al., J. Am. Chem. Soc. 74, 1491 (1952); Davidson, Meyer, ibid. 76, 5686 (1954). Structure: eidem, ibid. 77, 4796 (1955). Synthesis: Takanashi et al., ibid. 84, 3029 (1962). Chondrosine yields on acid hydrolysis chondrosamine (D-galactosamine, q.v.). Prepn and derivatives: Stacey, J. Chem. Soc. 1944, 272; Wolfrom, Onodera, J. Am. Chem. Soc. 79, 4737 (1957).